Capstone Investment Advisors
PCVX icon

Capstone Investment Advisors’s Vaxcyte PCVX Stock Holding History

Capstone Investment Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Buy
+4,666
New +$253K ﹤0.01% 1506
2025
Q4 		– Sell
-12,195
Closed -$439K – 1938
2025
Q3 		$439K Buy
+12,195
New +$404K ﹤0.01% 1466
2024
Q2 		– Sell
-109,389
Closed -$7.47M – 2366
2024
Q1 		$7.47M Buy
+109,389
New +$7.57M 0.03% 328

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Capstone Investment Advisors's PCVX Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Vaxcyte (PCVX) in Q2 2026: 4,666 shares worth $271K. The stake represents ﹤0.01% of the portfolio and ranks #1506 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in PCVX as recently as Q3 2025.

Capstone Investment Advisors first reported a position in PCVX in Q1 2024 and has held it in 3 quarters since. The position peaked at $7.47M in Q1 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Capstone Investment Advisors held 4,666 shares of Vaxcyte worth $271K as of Q2 2026.
  • Vaxcyte was a new Capstone Investment Advisors position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1506 holding.
  • Capstone Investment Advisors first reported a position in Vaxcyte in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Vaxcyte position peaked at $7.47M in Q1 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.